Discover how MCIT, TCET, TAP, and RAPID have shifted reimbursement expectations for MedTech.
CMS may eliminate the NTAP Alternative Pathway. Learn how this policy shift impacts Breakthrough Devices, reimbursement strategy, and MedTech adoption.
Learn why ASC-heavy medical technologies may benefit from launching in hospitals first, from shaping Medicare payment rates to building evidence and adoption momentum.
Understand how Medicare Advantage plans make coverage and payment decisions, and why MA strategy is essential for MedTech targeting Medicare-aged populations.